D, L., DA, S., K, P., C, B., NH, A. A., U, B., . . . AM, B. (2026). Hematologic Responses Achieved with Luspatercept in Higher-Risk Myelodysplastic Syndromes. Blood advances. https://doi.org/10.1182/bloodadvances.2025019244
Chicago Style (17th ed.) CitationD, Leonard, Sallman DA, Pugh K, Bell C, Al Ali NH, Borate U, Komrokji RS, and Brunner AM. "Hematologic Responses Achieved with Luspatercept in Higher-Risk Myelodysplastic Syndromes." Blood Advances 2026. https://doi.org/10.1182/bloodadvances.2025019244.
MLA (9th ed.) CitationD, Leonard, et al. "Hematologic Responses Achieved with Luspatercept in Higher-Risk Myelodysplastic Syndromes." Blood Advances, 2026, https://doi.org/10.1182/bloodadvances.2025019244.
Warning: These citations may not always be 100% accurate.
